New vaccine against Bovine Respiratory Disease: Boehringer Ingelheim reaffirms its focus on prevention

Ingelheim, Germany, 27 September 2018 – Boehringer Ingelheim’s Bovalto^® Respi Intranasal is a new respiratory vaccine for active immunization of cattle against the viruses Parainfluenza 3 Virus (PI3V) and Bovine Respiratory Syncytial Virus (BRSV).

It represents an important advance in safeguarding health of cattle against one of the most common cattle diseases spread worldwide.

BRD has a significant economic impact with costs estimated at 43 GBP per dairy calf and 82 GBP per suckler calf. Only 40 per cent of these costs represent vet fees and medicines; the other 60 per cent are hidden costs primarily resulting from mortality and a reduction in growth rates².

“This is an important step to control BRD in cattle,” explains Steve Williams, Global Head of Strategic Business Unit Ruminants at Boehringer Ingelheim. “Our long-term objective is to focus on prevention, not only BRD but also other diseases. Therefore, we plan to launch Bovalto® Respi Intranasal in cattle farming regions in order to provide a simple vaccination for a large benefit in the management of this respiratory disease in young cattle.”

Bovalto^® Respi Intranasal is the first cattle vaccine launched after Boehringer Ingelheim and Merial joined forces in 2016.

For further information on the Boehringer Ingelheim Animal Health Business Unit please view our corporate video.

Boehringer Ingelheim
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: https://annualreport.boehringer-ingelheim.com.

Boehringer Ingelheim Animal Health Business Unit
Boehringer Ingelheim is the second largest animal health business in the world. We are committed to creating animal wellbeing through our large portfolio of advanced, preventive healthcare products and services. With net sales of 3.9 billion euros and around 10,000 employees worldwide, we are present in more than 150 markets. For more information click here.

Further media channels:
www.newshome.com
www.facebook.com/boehringeringelheim
www.twitter.com/Boehringer
www.twitter.com/Boehringer_AH
www.youtube.com/user/boehringeringelheim
www.pinterest.com/biglobal/
www.instagram.com/boehringer_ingelheim

Intended audiences
This press release is issued from our Corporate Headquarters in Ingelheim, Germany, and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Footnotes

¹Economic impact associated with respiratory disease in beef cattle - Griffin D Vet Clin North Am Food Anim Pract. 1997 Nov; 13(3):367-77).

²Andrews A. H. (2000) Calf Pneumonia Costs! Cattle Practice 8(2)).